The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSI) resistance in advanced EGFR-mutant NSCLC: A phase II study (ABCD-study).
 
Akito Hata
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; MSD
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Taiho Pharmaceutical
Research Funding - AstraZeneca; AstraZeneca (Inst); Boehringer Ingelheim; Boehringer Ingelheim (Inst); Lilly; Lilly (Inst); MSD; MSD (Inst)
 
Nobuyuki Katakami
Research Funding - Boehringer Ingelheim; Chugai Pharma; Delta-Fly Pharma; MSD
 
Naoto Takase
No Relationships to Disclose
 
Kayoko Kibata
No Relationships to Disclose
 
Yuta Yamanaka
No Relationships to Disclose
 
Motohiro Tamiya
Honoraria - Asahi Kasei; Boehringer Ingelheim; Bristol Hospice; Chugai Pharma; Lilly; MSD; Ono Pharmaceutical; Taiho Oncology
 
Masahide Mori
Speakers' Bureau - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Kyowa Kirin; Lilly; MSD; Nihonkayaku; Novartis; Ono Pharmaceutical; Otsuka; Shionogi; Taiho Pharmaceutical; Takeda
 
Takashi Kijima
No Relationships to Disclose
 
Satoshi Morita
No Relationships to Disclose
 
Kazuko Sakai
No Relationships to Disclose
 
Kazuto Nishio
Speakers' Bureau - Amgen; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Company; Chugai Pharma; Fujirebio; Guardant Health; Janssen; Lilly Japan; Merck; MSD K.K.; Novartis; Otsuka; Pfizer; Roche; Solasia Pharma; SymBio Pharmaceuticals; Takeda; Yakult Honsha
Research Funding - Clinical Research Support Center Kyushu; Nichirei; Nippon Boehringer Ingelheim; North East Japan Study Group; Osaka Minami Hospital; Thoracic Oncology Research Group; West Japan Oncology Group